Phase I trials were completed using the latest generation of autologous and allogeneic tumor cell lines secreting GM-CSF (e.g., K-562, lymphoblast cells isolated from the bone marrow of a 53-year-old chronic myelogenous leukemia patient). This evidence concerns the gene CSF2 and neoplasm.